CEACAM5 and neoplasm: Analysis of the TARGET and EPOCH data demonstrated no differences for dosimetry for weeks 1 and 2, and no statistical difference in efficacy treatment outcomes by treatment week (ORR, tumour marker response [AFP for TARGET; CEA for EPOCH], PFS/hPFS [EPOCH only] and OS).